New data from the randomized PEMBRO-RT study demonstrate when an ICI-mediated Abscopal effect is most likely to occur in patients with stage IV NSCLC. Ralph Weichselbaum Sean Pitroda, M.D. Amy L. Cummings, MD PhD doi.org/10.1038/s43018…

New in #practicalRO: Three-Dimensional Radiation Therapy for Early Stage Glottic Cancer Using a 4-Field Technique. #radonc tinyurl.com/probrower1

New today in #PracticalRO: Joint guideline from ASTRO, ASCO & SSO on post-mastectomy radiation therapy for patients with breast cancer. Updated recommendations cover indications, dosing, fractionation & multidisciplinary techniques. #RadOnc #BreastCancer ow.ly/524k50WXGao

🔥now fully published: Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC Journal of Hepatology doi.org/10.1016/j.jhep… ✅"long-term" survival in HCC, we are getting there ESMO - Eur. Oncology EASL Education ILCA

🚨 #FDA approves subcutaneous pembrolizumab (Keytruda Qlex). PK comparability met; ORR 45% SC vs 42% IV in MK-3475A-D77 trial ~1–2 min admin—logistics win, efficacy preserved. #FDAApproval #Oncology #Immunotherapy #CancerResearch #NSCLC #Keytruda #Subcutaneous

New in the #RedJournal: The Ongoing Challenge of Radiation-Immunotherapy Optimization: From Preclinical Insights to Clinical Practice. #radonc tinyurl.com/rjpark

🏥Critical Evaluation of TNT in Rectal Cancer JCO Oncology Practice ✅4 main TNT RCTs 👇 ascopubs.org/doi/pdfdirect/… #cancer #oncology #MedX #rectal OncoAlert ASCO

Ahead of #ESMO25: The evolving position of T-DXd in DESTINY-Breast trials #breastcancer #bcsm

A retrospective cohort study involving children born between 1996 and 2016 suggests a significant but small associated increased risk of hematologic cancer among those exposed to radiation from medical imaging. Full study results: nej.md/41YXEHD Editorial: Studying

Squamous NSCLC: Current & Emerging Options 🌟 For years, sqNSCLC vs adenocarcinoma, fewer drivers, options & survival. Now, HARMONi-2 (ivonescimab PFS 11.1 vs 5.8 mo) & other emerging combos show real progress with meaningful benefit & no major bleeding. clinical-lung-cancer.com/article/S1525-…

🇪🇺 ESGO–ESTRO–ESP 2025 GUIDELINES UPDATE 🔹 Core Update 2023 FIGO staging + Molecular classification (POLEmut / MMRd / NSMP / p53abn) ➡️ Biology now defines stage, risk & therapy 🧪 Universal Testing ✅ MMR IHC ± MLH1 methylation → all ECs 🔍 POLE, p53, ER, HER2 testing →

NEJM reports 10-year results of the SUPREMO trial: PMRT modestly reduced locoregional recurrence but didn’t improve OS in intermediate-risk #breastcancer Importance of individualized treatment decisions reaffirmed. OncoAlert #Oncology LARVOL OncoDaily Sara Tolaney ONCO BRUNO

New in #practicalRO: A Case for Caution in a New Era of Managing Patients with Locally Advanced Non-Small Cell Lung Cancer: Fatal Bronchial-Esophageal Fistula After Neoadjuvant Chemo-Immunotherapy Followed by Definitive Chemoradiation Therapy. tinyurl.com/heintzelman1

5/ #DESTINYBreast05 in NEJM by Sibylle Loibl : In high-risk HER2+ early breast cancer with residual disease after neoadjuvant therapy, T-DXd (ENHERTU) improved DFS vs T-DM1 (HR 0.47)--Proud to see my friend Jame Abraham, MD, FACP Cleveland Clinic as part of this landmark trial.

In locally advanced rectal cancer, short course RT (25 Gy/5 fx) was less immunosuppressive than long-course RT, despite more advanced disease. SCRT showed faster lymphocyte recovery, lower NLR and higher intratumoral CD8+ and FOXP3+. This immune preserving profile provides a

Radiation oncology is changing fast. But radiation can still injure normal tissue. An excellent review in NEJM explains how modern RadOnc is reducing that risk: -Precision planning -Adaptive radiotherapy -Biologic personalization -AI-assisted treatment design the goal is

做生物、医学的朋友可以关注这个 skills：OpenClaw Medical Skills 震惊到，872个医学AI agent技能集全，从临床到生信、药物发现、医疗器械、健康管理一应俱全。 是时候让你的🦞学会医疗技巧了，一个🦞就是一个生物学信息医学信息专家： github.com/MedClaw-Org/Op…

做医学或搞生物的朋友，建议看一下这个 Medical Skills 技能库，给 OpenClaw 注入专业的医疗执行力。 收录了 872 个经过精心筛选的技能模块，覆盖了从基础的文献检索，到复杂的生物信息学分析全流程。 每个技能就是一个独立的知识模块，教 AI 怎么操作真实的数据库、API

🧬 Proton vs Photon in Oropharyngeal Cancer – TORPEdO Trial Is IMPT really better than IMRT? 📊 Phase III RCT (n=205) comparing ⚡ IMPT vs IMRT + concurrent cisplatin 🎯 Co-primary endpoints (12 months): •Feeding tube dependence / ≥20% weight loss •QoL (UW-QoL physical

🔥💉 Immunotherapy timing does NOT impact survival - morning 🌅 vs afternoon 🌙 makes no difference #ELCC26 LBA2 - i-TIMES answers a long-standing chronotherapy question in lung cancer 👇 🧬 Study population Advanced/metastatic NSCLC Pooled from 8 international RCTs 🌍 PSM